新型降糖药在非酒精性脂肪性肝病中的研究进展

Research progress of new hypoglycemic agents in nonalcoholic fatty liver disease

全世界范围内非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)的患病率迅速增加,已经成为肝脏移植的主要原因之一,而应用于临床NAFLD患者的药物数量甚少,NAFLD作为多系统的代谢性疾病之一,患者常伴发肥胖、2型糖尿病(type 2 diabetes mellitus,T2DM)及胰岛素抵抗(insulin resistance,IR)等,应用于T2DM及改善IR的新型降糖药已被发现在一定程度上可以逆转或抑制NAFLD进程。本文通过对新型降糖药应用于NAFLD中的临床研究进行分析总结,挖掘其治疗NAFLD的机制,总结新型降糖药在NAFLD中作用的研究进展,以期为NAFLD的临床用药提供新思路。

Worldwide nonalcoholic fatty liver disease(NAFLD)prevalence rate increased rapidly,it has become one of the main causes of liver transplantation,and the number of drugs used in clinical patients with NAFLD,as one of the multiple system of metabolic diseases,NAFLD patients are often associated with obesity,type 2 diabetes mellitus(T2DM)and insulin resistance(IR),etc.New hypoglycemic drugs applied to T2DM and improving IR have been found to reverse or inhibit the process of NAFLD to a certain extent.This paper analyzed and summarized the clinical studies on the application of new hypoglycemic agents in NAFLD,explored the mechanism of their treatment for NAFLD,and summarized the research progress of the role of new hypoglycemic agents in NAFLD,in order to provide new ideas for the clinical use of NAFLD.